Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.

Kan VL, Manischewitz J, King LR, Golding H.

AIDS. 2007 Feb 19;21(4):521-4.

PMID:
17301573
2.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

3.

Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.

J Infect Dis. 2003 Oct 15;188(8):1181-91. Epub 2003 Oct 10.

PMID:
14551889
4.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

5.

Unintended smallpox vaccination of HIV-1-infected individuals in the United States military.

Tasker SA, Schnepf GA, Lim M, Caraviello HE, Armstrong A, Bavaro M, Agan BK, Delmar J, Aronson N, Wallace MR, Grabenstein JD; US Department of Defense Tri-Service AIDS Clinical Consortium.

Clin Infect Dis. 2004 May 1;38(9):1320-2. Epub 2004 Apr 14.

PMID:
15127348
6.

Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome.

Bartlett JG.

Clin Infect Dis. 2003 Feb 15;36(4):468-71. Epub 2003 Jan 30.

PMID:
12567305
7.

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.

J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.

8.

Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.

Kennedy JS, Frey SE, Yan L, Rothman AL, Cruz J, Newman FK, Orphin L, Belshe RB, Ennis FA.

J Infect Dis. 2004 Oct 1;190(7):1286-94. Epub 2004 Aug 30.

PMID:
15346340
9.

Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.

Somekh E, Smetana Z, Tanay A, Dalal I, Babai I, Mendelson E.

Vaccine. 2004 Dec 2;23(3):321-4.

PMID:
15530675
10.

Dose-dependent neutralizing-antibody responses to vaccinia.

Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, Yan L.

J Infect Dis. 2004 Feb 1;189(3):493-7. Epub 2004 Jan 23.

PMID:
14745707
11.

The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.

Kim SH, Yeo SG, Park KH, Bang JW, Kim HB, Kim NJ, Jee Y, Cho H, Oh MD, Choe KW.

Clin Microbiol Infect. 2007 Jan;13(1):91-3.

12.

Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults.

Treanor J, Wu H, Liang H, Topham DJ.

Vaccine. 2006 Nov 17;24(47-48):6913-23. Epub 2006 Jun 21.

PMID:
17014939
13.

Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R.

J Immunol. 2003 Nov 15;171(10):4969-73.

14.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997
15.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325
16.

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.

Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.

Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/j.vaccine.2008.11.079. Epub 2008 Dec 9.

PMID:
19071184
17.

Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy.

Pütz MM, Alberini I, Midgley CM, Manini I, Montomoli E, Smith GL.

J Gen Virol. 2005 Nov;86(Pt 11):2955-60.

PMID:
16227216
18.

Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, Erfle V.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):782-93.

PMID:
17604541
19.

Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus.

Sirikwin S, Likanonsakul S, Waradejwinyoo S, Pattamadilok S, Kumperasart S, Chaovavanich A, Manatsathit S, Malerczyk C, Wasi C.

Vaccine. 2009 Jul 9;27(32):4350-4. doi: 10.1016/j.vaccine.2009.03.027. Epub 2009 Apr 3.

PMID:
19487057
20.

Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults.

Waibel KH, Golding H, Manischewitz J, King LR, Tuchscherer M, Topolski RL, Walsh DS.

Clin Infect Dis. 2006 Feb 15;42(4):e16-20. Epub 2006 Jan 10.

PMID:
16421781

Supplemental Content

Support Center